Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)

Status Completed

Clinical Trial Summary

A multi-center, randomized, controlled clinical trial to evaluate the short-term and long-term efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and preserving renal function in patients with IgAN who have pre-treated (and continue to be treated) with angiotensin II receptor blockers (ARB), compared to the corticosteroids.

Clinical Trial Description

There are four phases of study for each subject. Phase 1 the screening phase. During this phase each potential subject will be evaluated to determine if he/she is eligible for the study.

Phase 2 the ARB lead-in phase will last for three months. Phase 3 the intervention phase. Each subject will be randomly received 12 months treatment with the study drugs (MMF, prednisone or MMF plus prednisone) Phase 4 following-up phase. All the patients will be followed by 3 years after study drug stopped. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00657059
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Completed
Phase	Phase 3
Start date	September 2007
Completion date	May 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05016323` - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	Phase 2
Withdrawn	`NCT02433236` - Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy	Phase 2
Recruiting	`NCT02231125` - Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy	Phase 4
Completed	`NCT01502579` - An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data	N/A
Not yet recruiting	`NCT01203007` - Diet Intervention in Food Sensitive Patients With IgA Nephropathy	N/A
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Recruiting	`NCT04684745` - Open-Label Extension Study of BION-1301 in IgA Nephropathy	Phase 2
Completed	`NCT03719443` - First in Human Study to Assess Safety of VIS649 in Healthy Subjects	Phase 1
Completed	`NCT02112838` - Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	Phase 2
Withdrawn	`NCT02052219` - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy	Phase 3
Completed	`NCT00767221` - Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study	Phase 2
Recruiting	`NCT04438603` - The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Terminated	`NCT04905212` - A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy	Phase 2
Terminated	`NCT04042623` - Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy	Phase 2
Recruiting	`NCT03633864` - Fecal Microbiota Transplantation for Refractory IgA Nephropathy	Phase 2
Not yet recruiting	`NCT06454110` - Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)	Phase 2
Recruiting	`NCT02954419` - IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Recruiting	`NCT03001947` - IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Completed	`NCT01224028` - A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients	Phase 2